What question did this study set out to answer?

December 8, 2025BloodOpen Access

Distinct inflammatory and immune recovery patterns after CD19-directed CAR T-cell therapy in SLE and B-cell lymphoma

View Full Paper

Ask AI

Bookmark

Authors

NSNora Rebecca SchwingenFriedrich-Alexander-Universität Erlangen-Nürnberg MHMelanie HagenFriedrich-Alexander-Universität Erlangen-Nürnberg MAMichael AignerFriedrich-Alexander-Universität Erlangen-Nürnberg

Discussion

Member takes

Implication

Chimeric Antigen Receptor T-cell therapy shows distinct immune recovery in systemic lupus erythematosus compared to B-cell lymphoma, suggesting different inflammatory responses.

Key Points

This research aims to compare inflammation and immune recovery patterns after CD19-directed CAR T-cell therapy in systemic lupus erythematosus and B-cell lymphoma.
Conducted serum proteomics in SLE (N=18) and lymphoma patients (N=48) before and at intervals post CAR T-cell therapy.
Measured persistence of CAR T-cells and reconstitution of T- and B-cells using flow cytometry.
Analyzed serum inflammatory markers and cytokine levels using the Olink® Target 96 Immuno-Oncology Panel.
SLE patients displayed a resolution of IL-6-driven inflammation and reduced cytokines post therapy, unlike lymphoma patients.
IL-6, IL-1α, and CXCL10 levels were elevated before therapy in both groups.
SLE showed increased expression of immune-restorative cytokines like CXCL5 and TGF-b1 post therapy.
Principal component analysis revealed distinct clustering of SLE patients closer to healthy donors one year post therapy.

Cite This Study

Schwingen et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d59b https://doi.org/10.1182/blood-2025-1947

View Full Paper

Ask AI

Bookmark

Implication

Chimeric Antigen Receptor T-cell therapy shows distinct immune recovery in systemic lupus erythematosus compared to B-cell lymphoma, suggesting different inflammatory responses.

Distinct inflammatory and immune recovery patterns after CD19-directed CAR T-cell therapy in SLE and B-cell lymphoma

Discussion

Member takes

Implication

Key Points

Cite This Study

Distinct inflammatory and immune recovery patterns after CD19-directed CAR T-cell therapy in SLE and B-cell lymphoma

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider